期刊
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
卷 10, 期 -, 页码 -出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1758835918789364
关键词
alectinib; alectinib clinical trials; ALK; ALK inhibitors; ALK-rearranged NSCLC; ALK-TKI; ALK-tyrosine kinase inhibitors; EML4-ALK; non-small cell lung cancer; NSCLC
类别
Anaplastic lymphoma kinase (ALK) rearrangement is identified in 3-7% of advanced non-small cell lung cancer (NSCLC) cases, and ALK tyrosine kinase inhibitors (TKIs) have revolutionized the management of this subset of NSCLC patients. ALK-TKIs have been proven highly effective in ALK-rearranged advanced NSCLC patients, but after initial responses and benefit, a subsequent progression inevitably occurs. Understanding acquired-resistance mechanisms and defining an appropriate algorithm is becoming even more essential, particularly considering the availability of extremely efficacious next-generation ALK inhibitors. The aim of this review is the analysis of current data about ALK inhibition as a therapeutic strategy in ALK-rearranged NSCLC management, with a focus on a specific ALK-TKI, alectinib. Alectinib is a highly selective inhibitor of ALK and showed systemic and central nervous system (CNS) efficacy in the treatment of this particular population. The change of first-line approach, and consequently of further lines of therapy, in ALK-rearranged NSCLC patients is still a matter of debate. A summary of evidence from randomized trials evaluating alectinib will be presented in order to discuss the available clinical evidence, safety and place in therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据